Authors:
Rini Noviyani
1
;
P. A. Indrayathi
1
;
I. N. G. Budiana
1
;
Rasmaya Niruri
2
;
K. Tunas
3
and
Tamara Candra Paramitha
1
Affiliations:
1
Udayana University, Indonesia
;
2
Sebelas Maret University, Indonesia
;
3
Dhyana Pura University, Indonesia
Keyword(s):
Chemotherapy, Paclitaxel-cisplatin, Ovarian Cancer, CA 125, BUN, Creatinine Serum
Abstract:
The effectiveness and side effects of paclitaxel-cisplatin chemotherapy were assessed from the patient’s treatment progress and toxicity level. The objective was to evaluate these two criteria through the assessment of CA 125, BUN, and creatinine serum in patients as an approach to overcome the data limitation at Sanglah General Hospital. Observational retrospective research with patients who had epithelial ovarian cancer (EOC) at Stages I, II, III, and IV was conducted from February-March 2018. Patients’ blood samples were checked before the first and after the sixth cycle of chemotherapy. The data were processed with the Shapiro-Wilks normality test. As for the abnormally distributed data, they were analyzed statistically using the Wilcoxon test in SPSS. The mean values of CA 125 before the first and after the sixth chemotherapy cycles were 9,429.6 ± 1,5978.7 U/ml and 31.65 ± 36.07 U/ml, respectively (p-value= 0109). The mean values of BUN parameter were 10.63 ± 2.95 mg/dl and 14.8
3 ± 7.176 mg/dl (p-value= 0.315), respectively. The creatinine serums were averagely 0.693 ± 0.0929 mg/dl and 0.78 ± 0.2053 mg/dl (p-value= 0.417), respectively. There were differences in the levels of CA 125, BUN, and creatinine serum before the first and after the sixth cycles.
(More)